Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.83
CERS's Cash to Debt is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CERS: 4.83 )
CERS' s 10-Year Cash to Debt Range
Min: 0.62   Max: 14206.57
Current: 4.83

0.62
14206.57
Equity to Asset 0.60
CERS's Equity to Asset is ranked higher than
69% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CERS: 0.60 )
CERS' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.9
Current: 0.6

0.06
0.9
F-Score: 3
Z-Score: 0.75
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -109.20
CERS's Operating margin (%) is ranked higher than
71% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CERS: -109.20 )
CERS' s 10-Year Operating margin (%) Range
Min: -2168.13   Max: -7.75
Current: -109.2

-2168.13
-7.75
Net-margin (%) -67.75
CERS's Net-margin (%) is ranked higher than
74% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CERS: -67.75 )
CERS' s 10-Year Net-margin (%) Range
Min: -1946.68   Max: 53.6
Current: -67.75

-1946.68
53.6
ROE (%) -56.88
CERS's ROE (%) is ranked higher than
66% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CERS: -56.88 )
CERS' s 10-Year ROE (%) Range
Min: -248.74   Max: 46.03
Current: -56.88

-248.74
46.03
ROA (%) -31.14
CERS's ROA (%) is ranked higher than
72% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. CERS: -31.14 )
CERS' s 10-Year ROA (%) Range
Min: -122.82   Max: 16.26
Current: -31.14

-122.82
16.26
ROC (Joel Greenblatt) (%) -1057.18
CERS's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. CERS: -1057.18 )
CERS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8770.57   Max: -164.15
Current: -1057.18

-8770.57
-164.15
Revenue Growth (3Y)(%) 1.20
CERS's Revenue Growth (3Y)(%) is ranked higher than
79% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CERS: 1.20 )
CERS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -44.7   Max: 52.9
Current: 1.2

-44.7
52.9
EBITDA Growth (3Y)(%) 17.70
CERS's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CERS: 17.70 )
CERS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -52.9   Max: 123.5
Current: 17.7

-52.9
123.5
EPS Growth (3Y)(%) 15.10
CERS's EPS Growth (3Y)(%) is ranked higher than
88% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CERS: 15.10 )
CERS' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.1   Max: 21
Current: 15.1

-30.1
21
» CERS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CERS Guru Trades in Q4 2013

Chuck Royce 3,860,211 sh (-4.25%)
» More
Q1 2014

CERS Guru Trades in Q1 2014

Chuck Royce 3,807,005 sh (-1.38%)
» More
Q2 2014

CERS Guru Trades in Q2 2014

Chuck Royce 3,725,505 sh (-2.14%)
» More
Q3 2014

CERS Guru Trades in Q3 2014

Chuck Royce 3,765,505 sh (+1.07%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.60
CERS's P/B is ranked higher than
65% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CERS: 10.60 )
CERS' s 10-Year P/B Range
Min: 0.82   Max: 55
Current: 10.6

0.82
55
P/S 13.80
CERS's P/S is ranked higher than
79% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. CERS: 13.80 )
CERS' s 10-Year P/S Range
Min: 1.24   Max: 15.91
Current: 13.8

1.24
15.91
EV-to-EBIT -12.22
CERS's EV-to-EBIT is ranked higher than
76% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CERS: -12.22 )
CERS' s 10-Year EV-to-EBIT Range
Min: -77.8   Max: 0.9
Current: -12.22

-77.8
0.9
Current Ratio 3.43
CERS's Current Ratio is ranked higher than
67% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CERS: 3.43 )
CERS' s 10-Year Current Ratio Range
Min: 1.03   Max: 9.96
Current: 3.43

1.03
9.96
Quick Ratio 2.80
CERS's Quick Ratio is ranked higher than
66% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CERS: 2.80 )
CERS' s 10-Year Quick Ratio Range
Min: 1.03   Max: 9.96
Current: 2.8

1.03
9.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 32.20
CERS's Price/Net Cash is ranked higher than
75% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. CERS: 32.20 )
CERS' s 10-Year Price/Net Cash Range
Min: 1.88   Max: 103.13
Current: 32.2

1.88
103.13
Price/Net Current Asset Value 18.30
CERS's Price/Net Current Asset Value is ranked higher than
77% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. CERS: 18.30 )
CERS' s 10-Year Price/Net Current Asset Value Range
Min: 1.73   Max: 68
Current: 18.3

1.73
68
Price/Tangible Book 11.30
CERS's Price/Tangible Book is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. CERS: 11.30 )
CERS' s 10-Year Price/Tangible Book Range
Min: 0.92   Max: 300
Current: 11.3

0.92
300
Price/Median PS Value 2.40
CERS's Price/Median PS Value is ranked higher than
73% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CERS: 2.40 )
CERS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 92.9
Current: 2.4

0.24
92.9
Earnings Yield (Greenblatt) -8.00
CERS's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. CERS: -8.00 )
CERS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8   Max: 16235.6
Current: -8

-8
16235.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU2.Germany,
Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 15 issued or allowed United States patents and approximately 121 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations' blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.
» More Articles for CERS

Headlines

Articles On GuruFocus.com
hummm royce adding Oct 05 2011 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 
Cerus Corporation Announces Second Quarter Financial Results Jul 30 2009 
Cerus Corporation Extends Manufacturing Agreement with Fenwal Dec 15 2008 

More From Other Websites
Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint Dec 22 2014
8:30 am Cerus announced that its Phase 2 clinical trial of red blood cells treated with the... Dec 22 2014
Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint Dec 22 2014
US STOCKS-Wall St up for 3rd day, led by energy shares Dec 19 2014
US STOCKS-Wall St up for 3rd day, led by energy shares Dec 19 2014
New highs! The S&P 500 closes just below its prior record close... Dec 19 2014
US STOCKS-Wall St adds gains in late trade; energy leads Dec 19 2014
US STOCKS-Wall St adds gains in late trade; energy leads Dec 19 2014
US STOCKS-Wall St little changed after best two-day run in three years Dec 19 2014
US STOCKS-Wall St little changed after best two-day run in three years Dec 19 2014
FDA Approves INTERCEPT Blood System for Platelets Dec 18 2014
FDA Approves INTERCEPT Blood System for Platelets Dec 18 2014
Equity markets surge...so many stories – where to begin? Dec 17 2014
Cerus jumps on FDA OK for plasma treatment Dec 17 2014
Now it’s the Fed’s turn to pour grease on the market fire Dec 17 2014
FDA Approves INTERCEPT Blood System for Plasma Dec 16 2014
FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma Nov 21 2014
FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma Nov 21 2014
Study will test survivors' blood to treat Ebola Nov 18 2014
CERUS CORP Financials Nov 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK